Generate Biomedicines (GENB) Fundamental Analysis: Revenue, Earnings & Valuation

5.84 / 10

Netural

Fundamental analysis scores 5.8/10, indicating fair quality. Cash‑up and profit‑to‑market‑value are bullish, while cash‑to‑market‑value and asset‑to‑market‑value also rate positively. However, operating cash‑flow growth and interest coverage are weak, and net profit margin shows no strength, warranting caution.

Analysis Checks(7/10)

Revenue-MV

Value-0.26

Score3/3

Weight14.27%

1M Return10.49%

Net cash flow from operating activities per share (YoY growth rate %)

Value18.75

Score1/3

Weight2.09%

1M Return2.11%

Net profit attributable to parent company shareholders / Net profit (%)

Value100.00

Score1/3

Weight2.19%

1M Return2.26%

Profit-MV

Value-0.15

Score3/3

Weight12.68%

1M Return9.61%

Net income-Revenue

Value1.98

Score2/3

Weight7.06%

1M Return6.13%

PB-ROE

Value31.38

Score3/3

Weight11.67%

1M Return9.23%

Cash-UP

Value0.53

Score3/3

Weight8.97%

1M Return7.53%

Interest coverage ratio (EBIT / Interest expense) (%)

Value-167.64

Score1/3

Weight2.59%

1M Return2.65%

Asset-MV

Value-0.45

Score2/3

Weight17.83%

1M Return13.24%

Cash-MV

Value0.12

Score3/3

Weight20.65%

1M Return13.08%

Is GENB undervalued or overvalued?

GENB scores 5.84/10 on fundamentals and holds a Fair valuation at present. Backed by its 0.00% ROE, -699.10% net margin, -5.84 P/E ratio, 7.73 P/B ratio, and 0.00% earnings growth, these metrics solidify its Netural investment rating.